Trial Profile
A multicentre, open label, dose-escalation phase I trial in patients with advanced stage chronic heart failure (CHF)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2017
Price :
$35
*
At a glance
- Drugs AB 1002 (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2017 According to a NanoCor Therapeutics media release, the company expects to initiate this trial in 2018.
- 22 Apr 2016 New trial record